Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

"Duality of Interest. CANVAS and biomarker measurements were funded by Janssen Research & Development. CANVAS was conducted as a collaboration between the funder, an academic steering committee, and an academic research organization, The George Institute for Global Health. The funder was involved in the study design, data collection, data analysis, data interpretation, and writing of the manuscript. B.L.N. has received fees for travel support, advisory boards, and steering committee roles from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen, with all honoraria paid to his institution. B.N. has received grant funding, travel reimbursement, and consultancy fees paid to his institution related to his work on CANVAS and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE). C.A. is an employee of The George Institute for Global Health. She has received honoraria from Amgen and AstraZeneca (paid to her institution). V.P. has received fees for advisory boards, steering committee roles, or scientific presentations from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Baxter, Bristol Myers Squibb, Boehringer Ingelheim, Chinook, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Metavant, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Pfizer, PharmaLink, Relypsa, Retrophin, Sanofi, Servier, Vifor Pharma, Vitae, UpToDate, and Tricida. P.M.R. has received research grant support from and served as a consultant to Bristol Myers Squibb and Pfizer for work unrelated to this project, in addition to unrelated consulting for Corvidia Therapeutics, Novartis, Flame, AGEPHA Pharma, Inflazome, AstraZeneca, Janssen, CiVi Biopharma, SOCAR, Novo Nordisk, Uptton, OMEICOS Therapeutics, and Boehringer Ingelheim. K.R.T. reports other support from Eli Lilly and Gilead; personal fees and other support from Boehringer Ingelheim and AstraZeneca; grants, personal fees, and other support from Bayer AG and Novo Nordisk; grants and other support from Goldfinch Bio; and grants from Travere Therapeutics outside the submitted work. M.K.H. is an employee of Janssen Research & Development, LLC. H.J.L.H. has served as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly–Gilead, Goldfinch Bio, Janssen, Merck, Novo Nordisk, and Travere Therapeutics; and has received grant support from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Janssen. No other potential conflicts of interest relevant to this article were reported."

"Funding. T.S. is supported by the Biomarker Enterprise to Attack DKD (BEAt-DKD) project. The BEAt-DKD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement no. 115974. IMI2 JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. K.R.T. is supported by National Institutes of Health research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, and UM1AI109568 and Centers for Disease Control and Prevention contract 75D301-21-P-12254."